Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells

References

• Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447–59. doi:10.1016/S0140-6736(13)62120-0. PMID:25484026.
   PubMed Web of Science ®Google Scholar
• Karbasian Esfahani M, Morris EL, Dutcher JP, Wiernik PH. Blastic phase of chronic myelogenous leukemia. Curr Treat Options Onco.l. 2006;7:189–99. doi:10.1007/s11864-006-0012-y.
   PubMedGoogle Scholar
• Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: Mechanisms of blastic transformation. J Clin Invest. 2010;120:2254–64. doi:10.1172/JCI41246. PMID:20592475.
   PubMed Web of Science ®Google Scholar
• Koschmieder S, Vetrie D. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options. Semin Cancer Biol. 2017; S1044-579X(17)30152–9. doi:10.1016/j.semcancer.2017.07.006. PMID:28778403.
   PubMed Web of Science ®Google Scholar
• Heller G, Topakian T, Altenberger C, Cerny-Reiterer S, Herndlhofer S, Ziegler B, Datlinger P, Byrgazov K, Bock C, Mannhalter C, et al. Next generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia. Leukemia. 2016;30:1861–8. doi:10.1038/leu.2016.143. PMID:27211271.
   PubMed Web of Science ®Google Scholar
• Tabarestani S, Movafagh A. New developments in chronic myeloid leukemia: Implications for therapy. Iran J Cancer Prev. 2016;9:1–8.
   Web of Science ®Google Scholar
• Amabile G, Di Ruscio A, Müller F, Welner RS, Yang H, Ebralidze AK, Zhang H, Levantini E, Qi L, Martinelli G, et al. Dissecting the role of aberrant DNA methylation in human leukaemia. Nat Commun. 2015;6:7091. doi:10.1038/ncomms8091. PMID:25997600.
   PubMed Web of Science ®Google Scholar
• Jelinek J, Gharibyan V, Estecio MRH, Kondo K, He R, Chung W, Lu Y, Zhang N, Liang S, Kantarjian HM, et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011;6:1–9. doi:10.1371/journal.pone.0022110.
   Web of Science ®Google Scholar
• Fatemi M, Wade PA. MBD family proteins: reading the epigenetic code. J Cell Sci 2006;119:3033–7. doi:10.1242/jcs.03099. PMID:16868031.
   PubMed Web of Science ®Google Scholar
• Zhao X, Ueba T, Christie BR, Barkho B, McConnell MJ, Nakashima K, Lein ES, Eadie BD, Willhoite AR, Muotri AR, et al. Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proc Natl Acad Sci. 2003;100:6777–82. doi:10.1073/pnas.1131928100. PMID:12748381.
   PubMed Web of Science ®Google Scholar
• Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 2001;15:710–23. doi:10.1101/gad.194101. PMID:11274056.
   PubMed Web of Science ®Google Scholar
• Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet. 2001;27:322–6. doi:10.1038/85899. PMID:11242117.
   PubMed Web of Science ®Google Scholar
• Sansom OJ, Zabkiewicz J, Bishop SM, Guy J, Bird A, Clarke AR. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene. 2003;22:7130–6. doi:10.1038/sj.onc.1206850. PMID:14562041.
   PubMed Web of Science ®Google Scholar
• Cook PC, Owen H, Deaton AM, Borger JG, Brown SL, Clouaire T, Jones GR, Jones LH, Lundie RJ, Marley AK, et al. A dominant role for the methyl-CpG-binding protein Mbd2 in controlling Th2 induction by dendritic cells. Nat Commun. 2015;6:1–11. doi:10.1038/ncomms7920.
   Web of Science ®Google Scholar
• Berger J, Bird A. Role of MBD2 in gene regulation and tumorigenesis. Biochem Soc Trans. 2005;33:1537–40. doi:10.1042/BST0331537. PMID:16246164.
   PubMed Web of Science ®Google Scholar
• Mian OY, Wang SZ, Zhu SZ, Gnanapragasam MN, Graham L, Bear HD, Ginder GD. Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol Cancer Res. 2011;9:1152–62. doi:10.1158/1541-7786.MCR-11-0252. PMID:21693597.
   PubMed Web of Science ®Google Scholar
• Stefanska B, Suderman M, Machnes Z, Bhattacharyya B, Hallett M, Szyf M. Transcription onset of genes critical in liver carcinogenesis is epigenetically regulated by methylated DNA-binding protein MBD2. Carcinogenesis. 2013;34:2738–49. doi:10.1093/carcin/bgt273. PMID:23955541.
   PubMed Web of Science ®Google Scholar
• Campbell PM, Bovenzi V, Szyf M. Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. Carcinogenesis. 2004;25:499–507. doi:10.1093/carcin/bgh045. PMID:14688029.
   PubMed Web of Science ®Google Scholar
• Zhou M, Zhou K, Cheng L, Chen X, Wang J, Wang X-M, Zhang Y, Yu Q, Zhang S, Wang D, et al. MBD2 ablation impairs lymphopoiesis and impedes progression and maintenance of T-ALL. Cancer Res. 2018; canres.1434.2017. doi:10.1158/0008-5472.CAN-17-1434. PMID:29330145.
   PubMed Web of Science ®Google Scholar
• Zhang XK, Yang L, Liu XJ, Nie ZY, Wang XZ, Pan YX, Luo JM. Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia. Br J Haematol. 2017;178(5):728–38. doi:10.1111/bjh.14739. PMID:28480959.
   PubMed Web of Science ®Google Scholar
• Yin L, Ahmad R, Kosugi M, Kawano T, Avigan D, Stone R, Kharbanda S, Kufe D. Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. Cancer Biol Ther. 2010;10:483–91. doi:10.4161/cbt.10.5.12584. PMID:20592495.
   PubMed Web of Science ®Google Scholar
• Hongy Z, Xiaoy M, Yang Y, Han Z, Cao Y, Li C, Wu Y, Gong Q, Zhou X, Xu D, et al. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation. Carcinogenesis. 2011;32:1550–8. doi:10.1093/carcin/bgr176. PMID:21803735.
   PubMed Web of Science ®Google Scholar
• Cai H, Qin X, Yang C. Dehydrocostus lactone suppresses proliferation of human chronic myeloid leukemia cells through Bcr/Abl-JAK/STAT signaling pathways. J Cell Biochem. 2017;118:3381–90. doi:10.1002/jcb.25994. PMID:28300289.
   PubMed Web of Science ®Google Scholar
• Hedvat M, Huszar D, Herrmann A, Gozgit JM, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, et al. The JAK2 Inhibitor, AZD1480, Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors. Cancer Cell. 2009;16(6):487–497. doi:10.1016/j.ccr.2009.10.015. PMID:19962667.
   PubMed Web of Science ®Google Scholar
• Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, Cairncross JG, Weiss S. On-target JAK2 / STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro-oncology. 2012;15:198–207. doi:10.1093/neuonc/nos302. PMID:23262510
   PubMed Web of Science ®Google Scholar
• Valentino L, Pierre J. JAK/STAT signal transduction: Regulators and implication in hematological malignancies. Biochem Pharmacol. 2006;71:713–21. doi:10.1016/j.bcp.2005.12.017. PMID:16426581.
   PubMed Web of Science ®Google Scholar
• Chim CS, Wong ASY, Kwong YL. Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias. Ann Hematol. 2004;83:527–32. doi:10.1007/s00277-004-0843-1. PMID:14762685.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Hu G, Offer SM, Wellik LE, Han JJ, Stenson MJ, Dogan A, Diasio RB, Gupta M. Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy. Leukemia. 2014;28:147–54. doi:10.1038/leu.2013.251. PMID:23979523.
   PubMed Web of Science ®Google Scholar
• Oka T, Ouchida M, Koyama M, Lymphomas L. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias / lymphomas. Cancer Res. 2002 Nov 15;62(22):6390–4.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao D, Zhao H, Wu X, Zhao W, Wang Y, Xia B, Da W. Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis. Med Oncol. 2012;29:2359–63 doi:10.1007/s12032-012-0163-6. PMID:22258937.
   PubMed Web of Science ®Google Scholar
• Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood. 2004;103:4630–5. doi:10.1182/blood-2003-06-2007. PMID:14976049.
   PubMed Web of Science ®Google Scholar
• Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood. 2006;108:2796–803. doi:10.1182/blood-2006-04-017434. PMID:16825495.
   PubMed Web of Science ®Google Scholar
• Lin L, Deangelis S, Foust E, Fuchs J, Li C, Li P-K, Schwartz EB, Lesinski GB, Benson D, Lü J, et al. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer. 2010;9:217. doi:10.1186/1476-4598-9-217. PMID:20712901.
   PubMed Web of Science ®Google Scholar
• Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002;21:7137–46 doi:10.1038/sj.onc.1205942. PMID:12370803.
   PubMed Web of Science ®Google Scholar
• Ma L, Zhu Z, Jiang L, Sun X, Lu X, Zhou M, Qian S, Jianyong L. Matrine suppresses cell growth of human chronic myeloid leukemia cells via its inhibition of the interleukin-6/Janus activated kinase/signal transducer and activator of transcription 3 signaling cohort. Leuk Lymphoma. 2015;56:2923–30. doi:10.3109/10428194.2015.1007507. PMID:25629992.
   PubMed Web of Science ®Google Scholar
• Jung JH, Kwon T, Jeong S, Kim E, Sohn EJ, Yun M, Kim S. Apoptosis induced by tanshinone IIA and cryptotanshinone is mediated by distinct JAK / STAT3 / 5 and SHP1 / 2 signaling in chronic myeloid leukemia K562 cells. Evid Based Complement Alternat Med. 2013;2013:805639. doi:10.1155/2013/805639. PMID:23878608.
   PubMedGoogle Scholar
• Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol. 1996;16:6985–92. doi:10.1128/MCB.16.12.6985. PMID:8943354.
   PubMed Web of Science ®Google Scholar
• Bruecher-Encke B, Griffin JD, Neel BG, Lorenz U. Role of the tyrosine phosphatase SHP-1 in K 562 cell differentiation. Leukemia. 2001 Sep;15(9):1424–32. doi:10.1038/sj.leu.2402214.
   PubMed Web of Science ®Google Scholar
• Jiang L, Luo J. Role and mechanism of decitabine combined with tyrosine kinase inhibitors in advanced chronic myeloid leukemia cells. Oncol Lett. 2017;14(2):1295–302. doi:10.3892/ol.2017.6318. PMID:28789344.
   PubMed Web of Science ®Google Scholar
• Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'Brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JPJ. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007;109:899–906. doi:10.1002/cncr.22470. PMID:17236224.
   PubMed Web of Science ®Google Scholar
• Gu J, Li TJ, Zhao L, Liang X, Fu X, Wang J, Shang Z, Huang W, Zhou J. Identification of significant pathways induced by PAX5 haploinsufficiency based on protein-protein interaction networks and Cluster analysis in Raji Cell Line. Biomed Res Int. 2017;2017(7):5326370. doi:10.1155/2017/5326370. PMID: 28316978.
   PubMedGoogle Scholar
• Jung Y-S, Jun S, Lee SH, Sharma A, Park J-I. Wnt2 complements Wnt/β-catenin signaling in colorectal cancer. Oncotarget. 2015;6:37257–68. doi:10.18632/oncotarget.6133. PMID:26484565.
   PubMed Web of Science ®Google Scholar
• Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308. doi:10.1038/nprot.2013.143. PMID:24157548.
   PubMed Web of Science ®Google Scholar
• Wang J, Li T, Zhou M, Hu Z, Zhou X, Zhou S, Wang N, Huang L, Zhao L, Cao Y, et al. TALENs-mediated gene disruption of FLT3 in leukemia cells: using genome-editing approach for exploring the molecular basis of gene abnormality. Sci Rep. 2015;5:1–13.
   Web of Science ®Google Scholar